The fluctuating motor response to levodopa in Parkinson's disease (""""""""on-off"""""""" phenomenon) is a common, disabling problem that occurs during chronic levodopa therapy and is resistant to current modes of therapeutic manipulation. In addition to fluctuations in motor function, fluctuations in mood, sensory symptoms and autonomic function are also common and can be incapacitating. Our goal is to understand how the fluctuating response develops and what factors determine motor function and mood at any point in time. This understanding is the foundation on which to design improved therapeutic strategies to reduce fluctuations or prevent their development.
The aims of this clinical study are: 1. Investigate """"""""off"""""""" periods that occur during constant rate levodopa infusions to determine if a. they are dose responsive, that is, occur at lower but not higher infusion rates, b. their frequency is altered by the length of infusion, c. they occur during elevations of plasma large neutral amino acids or 3-O-methyldopa which could block levodopa's entry into brain. 2. Define temporal relation between mood and plasma levodopa and motor function and determine if levodopa-induced fluctuations in mood are a trait or state marker for depression. 3. Explore possibility that """"""""off"""""""" periods represent a negative levodopa effect rather than absence of positive or beneficial levodopa effect by a. examining response to stepwise subtherapeutic infusions to look for a biphasic response to levodopa and b. examining """"""""off"""""""" periods after short and long infusions for evidence of withdrawal phenomena. 4. Examine the """"""""long duration"""""""" response to levodopa by a. determining the rate of decline in motor function when levodopa is withheld for 2 to 3 days and correlating the rate of decline with disease severity, duration of levodopa therapy and concurrent medications and b. examining the recovery of the """"""""long duration"""""""" response after the mini-holiday with diurnal and nocturnal levodopa infusions and apomorphine infusions. 5. Follow a small cohort of parkinsonian patients from the initiation of levodopa therapy to study the emergence of the """"""""short"""""""" and """"""""long"""""""" duration responses to levodopa as well as dyskinesia and """"""""negative"""""""" levodopa actions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS021062-10
Application #
3401838
Study Section
Neurology A Study Section (NEUA)
Project Start
1984-07-01
Project End
1996-06-30
Budget Start
1993-07-01
Budget End
1994-06-30
Support Year
10
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
Schools of Medicine
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Holford, Nick H G; Nutt, John G (2011) Interpreting the results of Parkinson's disease clinical trials: time for a change. Mov Disord 26:569-77
Zampieri, Cris; Salarian, Arash; Carlson-Kuhta, Patricia et al. (2011) Assessing mobility at home in people with early Parkinson's disease using an instrumented Timed Up and Go test. Parkinsonism Relat Disord 17:277-80
Brodsky, Matthew A; Park, Byung S; Nutt, John G (2010) Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease. Arch Neurol 67:27-32
Nutt, John G; Chung, Kathy A; Holford, Nicholas H G (2010) Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology 74:1191-7
Chung, Kathryn A; Lobb, Brenna M; Nutt, John G et al. (2010) Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 75:1263-9
Kay, D M; Stevens, C F; Hamza, T H et al. (2010) A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 75:1189-94
Chung, Kathryn A; Lobb, Brenna M; Nutt, John G et al. (2010) Objective measurement of dyskinesia in Parkinson's disease using a force plate. Mov Disord 25:602-8
Gunzler, Steven A; Pavel, Misha; Koudelka, Caroline et al. (2009) Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials. Clin Neuropharmacol 32:97-102
Peterson, Amie L; Nutt, John G (2008) Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5:270-80
Holford, Nick; Nutt, John G (2008) Disease progression, drug action and Parkinson's disease: why time cannot be ignored. Eur J Clin Pharmacol 64:207-16

Showing the most recent 10 out of 68 publications